Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
about
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseRational Combinations of Targeted Agents in AMLMolecular profiling of childhood cancer: Biomarkers and novel therapiesNovel therapies for children with acute myeloid leukaemia.A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.
P2860
Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@en
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@nl
type
label
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@en
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@nl
prefLabel
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@en
Adaptation of the plasma inhib ...... AT9283 in pediatric leukemia.
@nl
P2093
P1433
P1476
Adaptation of the plasma inhib ...... y AT9283 in pediatric leukemia
@en
P2093
Andrew D J Pearson
Jennifer E Podesta
Matt Squires
Richard Sugar
P304
P356
10.1016/J.LEUKRES.2011.05.022
P577
2011-06-12T00:00:00Z